A Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors:A Multicenter, Open-Label, Dose-Escalation and Multiple Cohort Dose Expansion Phase 1b Clinical Trial
Latest Information Update: 16 May 2025
At a glance
- Drugs HC 006 (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors HC Biopharma
Most Recent Events
- 16 May 2025 New trial record